pacira pharmaceuticals, inc. (nasdaq: pcrx) is an emerging specialty pharmaceutical company focused on the clinical and commercial development of new products that meet the needs of acute care practitioners and their patients. the company's current emphasis is the development of non-opioid products for postsurgical pain control, and its lead product, exparel® (bupivacaine liposome injectable suspension), was commercially launched in the united states in april 2012. exparel and two other products have utilized the pacira proprietary product delivery technology depofoam®, a unique platform that encapsulates drugs without altering their molecular structure and then releases them over a desired period of time.
Company profile
Ticker
PCRX
Exchange
Website
CEO
David M. Stack
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Blue Acquisition Corp, PACIRA INC, Pacira Pharmaceuticals, Inc.
SEC CIK
Corporate docs
Subsidiaries
Pacira Pharmaceuticals, Inc. • Pacira CryoTech, Inc. • Pacira Therapeutics, Inc. • Pacira Pharmaceuticals International, Inc. • Pacira Limited • Pacira Ireland Limited ...
PCRX stock data
Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
22 Apr 24
DEFA14A
Additional proxy soliciting materials
22 Apr 24
DEF 14A
Definitive proxy
22 Apr 24
S-8
Registration of securities for employees
29 Feb 24
10-K
2023 FY
Annual report
29 Feb 24
8-K
Pacira BioSciences Reports Fourth Quarter and Full-Year 2023 Financial Results
29 Feb 24
8-K
Pacira Reports Preliminary Unaudited Fourth Quarter and Full-Year 2023 Revenues
4 Jan 24
8-K
Pacira Appoints Frank D. Lee as Chief Executive Officer
21 Dec 23
10-Q
2023 Q3
Quarterly report
2 Nov 23
8-K
Pacira BioSciences Reports Third Quarter 2023 Financial Results
2 Nov 23
Transcripts
PCRX
Earnings call transcript
2023 Q4
29 Feb 24
PCRX
Earnings call transcript
2023 Q3
2 Nov 23
PCRX
Earnings call transcript
2023 Q2
2 Aug 23
PCRX
Earnings call transcript
2023 Q1
3 May 23
PCRX
Earnings call transcript
2022 Q4
28 Feb 23
PCRX
Earnings call transcript
2022 Q3
3 Nov 22
PCRX
Earnings call transcript
2022 Q2
3 Aug 22
PCRX
Earnings call transcript
2022 Q1
4 May 22
PCRX
Earnings call transcript
2021 Q4
24 Feb 22
PCRX
Earnings call transcript
2021 Q3
3 Nov 21
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 99.12 mm | 99.12 mm | 99.12 mm | 99.12 mm | 99.12 mm | 99.12 mm |
Cash burn (monthly) | (no burn) | 858.75 k | (no burn) | (no burn) | (no burn) | (no burn) |
Cash used (since last report) | n/a | 5.97 mm | n/a | n/a | n/a | n/a |
Cash remaining | n/a | 93.15 mm | n/a | n/a | n/a | n/a |
Runway (months of cash) | n/a | 108.5 | n/a | n/a | n/a | n/a |
Institutional ownership, Q3 2023
13F holders | Current |
---|---|
Total holders | 255 |
Opened positions | 41 |
Closed positions | 38 |
Increased positions | 96 |
Reduced positions | 83 |
13F shares | Current |
---|---|
Total value | 1.44 tn |
Total shares | 47.69 mm |
Total puts | 300.50 k |
Total calls | 342.80 k |
Total put/call ratio | 0.9 |
Largest owners | Shares | Value |
---|---|---|
BLK Blackrock | 7.51 mm | $230.31 bn |
Vanguard | 4.96 mm | $152.07 bn |
Frontier Capital Management | 1.80 mm | $55.21 bn |
STT State Street | 1.79 mm | $54.77 bn |
MCQEF Macquarie | 1.66 mm | $50.99 bn |
Baillie Gifford & Co | 1.64 mm | $50.23 bn |
Renaissance Technologies | 1.61 mm | $49.59 bn |
Dimensional Fund Advisors | 1.39 mm | $42.76 bn |
Stephens Investment Management | 1.34 mm | $41.22 bn |
Prosight Management | 1.21 mm | $37.13 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
8 Mar 24 | Pace Gary W | Common Stock | Sell | Dispose S | No | No | 30.6 | 90,000 | 2.75 mm | 22,127 |
7 Mar 24 | Pace Gary W | Common Stock | Sell | Dispose S | No | No | 30.81 | 28,257 | 870.60 k | 112,127 |
6 Mar 24 | Pace Gary W | Common Stock | Sell | Dispose S | No | No | 29.67 | 1,066 | 31.63 k | 140,384 |
5 Feb 24 | Williams Kristen Marie | Common Stock | Grant | Acquire A | No | No | 0 | 33,700 | 0.00 | 59,075 |
5 Feb 24 | Daryl Gaugler | Common Stock | Grant | Acquire A | No | No | 0 | 33,700 | 0.00 | 65,493.584 |
3 Jan 24 | Frank D. Lee | Stock Option Common Stock | Grant | Acquire A | No | No | 32.07 | 692,512 | 22.21 mm | 692,512 |
2 Jan 24 | Frank D. Lee | Common Stock | Grant | Acquire A | No | No | 0 | 99,520 | 0.00 | 99,520 |
News
A Glimpse Into The Expert Outlook On Pacira BioSciences Through 6 Analysts
9 Apr 24
Needham Reiterates Buy on Pacira BioSciences, Maintains $45 Price Target
9 Apr 24
JP Morgan Assumes Pacira BioSciences at Overweight, Announces Price Target of $45
7 Mar 24
HC Wainwright & Co. Reiterates Buy on Pacira BioSciences, Maintains $57 Price Target
4 Mar 24
Navigating 4 Analyst Ratings For Pacira BioSciences
1 Mar 24
Press releases
Thinking about buying stock in Healthequity, Pacira Biosciences, Interpublic Group of Companies, SIGA Technologies, or Sensus Healthcare?
21 Mar 24
Beyond the Pill: Athletes Champion PEMF and Non-Opioid Solutions for Pain Management (ENDV)
20 Mar 24
Pacira BioSciences Announces PCRX-201 Granted Regenerative Medicine Advance Therapy (RMAT) Designation for the Treatment of Osteoarthritis of the Knee
13 Mar 24
Pacira to Report 2023 Financial Results on Thursday February 29, 2024
22 Feb 24
Pacira Announces Publication of Pivotal Study of EXPAREL as a Sciatic Nerve Block in the Popliteal Fossa for Patients After Bunionectomy
15 Feb 24